Provided By GlobeNewswire
Last update: Aug 14, 2024
SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the second quarter ended June 30, 2024, and provided recent business highlights.
Read more at globenewswire.comNASDAQ:TSBX (7/22/2025, 1:13:49 PM)
0.3558
0 (-0.14%)
Find more stocks in the Stock Screener